Recent Multiple Myeloma News

AbbVie and the International Myeloma Foundation Partner to Study Role of a Genetic Mutation in Multiple Myeloma

(March 28, 2018)

AbbVie a research and development-based global biopharmaceutical company, and the International Myeloma Foundation (IMF) today announced they have entered into a collaboration to conduct a landmark retrospective... Continue Reading


CRISPR Enhances Cancer Immunotherapy

(March 14, 2018)

Gene editing expands reach of therapeutic T cells, in mice CancerConnect News: Last year, the Food and Drug Administration approved the first cellular immunotherapies to treat cancer. These therapies involve... Continue Reading


Darzalex-Effective Treatment for Smoldering Multiple Myeloma

(March 7, 2018)

CancerConnect News: The use of Darzalex (daratumumab) in smoldering myeloma may be effective in delaying the time to disease progression. These results were presented at the 2017 annual meeting of the... Continue Reading


Kyprolis Improves Survival in Recurrent Multiple Myeloma

(February 8, 2018)

CancerConnect News: The addition of Kyprolis® (carfilzomib) to the standard treatment regimen, Revlimid® (lenalidomide) and dexamethasone, improves survival for patients with multiple myeloma whose disease... Continue Reading


Diagnosed with Multiple Myeloma: 10 Tips on How to Get The Most From Your Doctor

(February 7, 2018)

1) Choose Your Doctor Carefully Hematologists and oncologists are the primary doctors involved with multiple myeloma and often work in collaboration with stem cell transplant physicians. Pick your primary... Continue Reading


Xgeva Approved for The Treatment of Multiple Myeloma

(January 17, 2018)

CancerConnect News: The US Food and Drug Administration (FDA) has expanded the approval of Xgeva (denosumab) for the prevention of skeletal-related events in patients with bone metastasis from multiple... Continue Reading


Addition of Darzalex™ Improves Outcomes in Newly Diagnosed Multiple Myeloma

(December 13, 2017)

The addition of Darzalex (daratumumab) to the standard treatment combination consisting of Velcade (bortezomib), melphalan, and prednisone (VMP) reduces disease progression or death by 50%, among patients... Continue Reading


FDA Adds Two Roche Multiple Myeloma Studies Evaluating Checkpoint Inhibitors to List of Partial Clinical Holds Over Safety Concerns

(September 25, 2017)

Alarmed that an imbalance in deaths among patients taking a combination of Keytruda (pembrolizumab) with Celgene’s Pomalyst and Revlimid could represent a threat in that whole class of checkpoint comboinations,... Continue Reading